scholarly journals Clinical Characteristics and Current Treatment of Age-Related Macular Degeneration

2014 ◽  
Vol 5 (1) ◽  
pp. a017178-a017178 ◽  
Author(s):  
Y. Yonekawa ◽  
I. K. Kim
Keyword(s):  
Macular Degeneration ◽  
Clinical Characteristics ◽  
Current Treatment ◽  
Age Related Macular Degeneration ◽  
Age Related

Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK

2013 ◽  
Vol 97 (9) ◽  
pp. 1168-1172 ◽  
Author(s):  
Tiarnan D L Keenan ◽  
Simon P Kelly ◽  
Ahmed Sallam ◽  
Quresh Mohamed ◽  
Adnan Tufail ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Clinical Characteristics ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
The Uk

Clinical Characteristics of Exudative Age-related Macular Degeneration in Japanese Patients

2007 ◽  
Vol 144 (1) ◽  
pp. 15-22.e2 ◽  
Author(s):  
Ichiro Maruko ◽  
Tomohiro Iida ◽  
Masaaki Saito ◽  
Dai Nagayama ◽  
Kuniharu Saito
Keyword(s):  
Macular Degeneration ◽  
Clinical Characteristics ◽  
Japanese Patients ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Age-related Macular Degeneration—Disease, Risk Factors, and Treatments

2014 ◽  
Vol 07 (02) ◽  
pp. 154
Author(s):  
Clyde Schultz ◽  
Keyword(s):  
Risk Factors ◽  
Macular Degeneration ◽  
Genetic Factors ◽  
Progressive Disease ◽  
Disease Risk ◽  
Treatment Options ◽  
Current Treatment ◽  
Posterior Segment ◽  
Age Related Macular Degeneration ◽  
Age Related

Age-related macular degeneration (AMD) is a progressive disease of the posterior segment of the eye. It is has been diagnosed worldwide and primarily affects individuals over 50 years of age. The incidence of the disease increases with age and with the presence of certain genetic factors, which may indicate a disposition for disease progression. In addition to genetic factors and age, other factors may be involved in developing AMD. These include obesity and smoking, which are also linked to various cardiovascular conditions. There are two forms of AMD: wet and dry. Both forms may involve the build-up of drusen deposits in the posterior segment of the eye, but the wet form tends to be more severe due to the proliferation of blood vessels into the macula and retinal areas of the back of the eye, thus causing an individual’s vision to become ‘blocked’ or ‘shaded’ usually beginning at the center of the visual field. There are a variety of treatment options for AMD including surgery in the form of laser or photo therapy. The most current treatment options involve the injection of a biologic into the posterior segment of the eye. There are some severe adverse events with this approach but they tend to be rare.

Macular Degeneration: An Overview

1991 ◽  
Vol 85 (6) ◽  
pp. 249-252 ◽  
Author(s):  
L.M. Chalifoux
Keyword(s):  
Macular Degeneration ◽  
Visual Loss ◽  
Psychosocial Problems ◽  
Current Treatment ◽  
Age Related Macular Degeneration ◽  
Age Related

This article presents an overview of information on macular degeneration for professionals who help persons with the disease adjust to their visual loss. It covers the types of macular degeneration, the etiology of the disease, and current treatment. In addition, it presents a composite case study, drawn from recent research, on the psychosocial problems and other difficulties that persons with age-related macular degeneration face.

scholarly journals Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches

2020 ◽  
Vol 21 (21) ◽  
pp. 8242
Author(s):  
Federico Ricci ◽  
Francesco Bandello ◽  
Pierluigi Navarra ◽  
Giovanni Staurenghi ◽  
Michael Stumpp ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Repeated Administration ◽  
Current Treatment ◽  
Age Related Macular Degeneration ◽  
Significant Advance ◽  
Neovascular Amd ◽  
Significant Treatment ◽  
Anti Vegf ◽  
Age Related ◽  
Ankyrin Repeat Proteins

Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. Despite therapeutic advances in the management of neovascular AMD, none of the currently used treatments cures the disease or reverses its course. Medical treatment of neovascular AMD experienced a significant advance due to the introduction of vascular endothelial growth factor inhibitors (anti-VEGF), which dramatically changed the prognosis of the disease. However, although anti-VEGF therapy has become the standard treatment for neovascular AMD, many patients do not respond adequately to this therapy or experience a slow loss of efficacy of anti-VEGF agents after repeated administration. Additionally, current treatment with intravitreal anti-VEGF agents is associated with a significant treatment burden for patients, caregivers, and physicians. New approaches have been proposed for treating neovascular AMD. Among them, designed ankyrin repeat proteins (DARPins) seem to be as effective as monthly ranibizumab, but with greater durability, which may enhance patient compliance with needed injections.

Clinical characteristics and outcomes after 5 yearspro re natatreatment of neovascular age-related macular degeneration with ranibizumab

2014 ◽  
Vol 93 (6) ◽  
pp. e511-e512 ◽  
Author(s):  
Archana Airody ◽  
Divya Venugopal ◽  
Victoria Allgar ◽  
Richard P. Gale
Keyword(s):  
Macular Degeneration ◽  
Clinical Characteristics ◽  
Age Related Macular Degeneration ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document